news

in the field of pharmaceutical innovation, every technological breakthrough and application carries the expectations of many patients. recently, yitong, a well-known domestic pharmaceutical company, announced that the company's product yiruiping® original research and localization technology transfer application has been officially approved by the national medical products administration. this good news not only marks that yitong has taken another solid step in the field of drug research and development and production, but also injects new vitality into the independent control and high-quality development of china's pharmaceutical industry.

2019in 2018, yitong acquired the relevant assets of yiruiping® and became its chinese drug marketing authorization holder; in 2020, the respiratory preparation factory of yitong pharmaceutical (suzhou) co., ltd., a subsidiary of yitong, successfully obtained a drug production license, and in 2023 passed the drug registration on-site verification of yiruiping® production by the state food and drug administration and the gmp compliance inspection (two-in-one inspection) by the jiangsu provincial food and drug administration. the approval of yitong yiruiping® original research and development localization technology transfer application marks a milestone in pharmaceutical innovation and localized production by yitong pharmaceutical. through technology transfer and localization, the production of yiruiping®, an original research drug, will no longer be restricted by external supply chains, but will be able to achieve high-quality and efficient manufacturing in china, which will have a far-reaching impact on enhancing the self-sufficiency and international competitiveness of my country's pharmaceutical industry.

as we all know, technology transfer is a key link from pharmaceutical research and development to commercial production. it not only requires strict adherence to scientific norms to ensure the consistency and stability of drug quality, but also requires consideration of production costs, efficiency, environmental friendliness and other factors. in the process of promoting the transfer of yiruiping® original research and development localization technology, yitong has fully utilized the company's comprehensive advantages in drug research and development, production management and quality control, and ensured the efficiency and success of technology transfer through continuous optimization of process flow, improvement of equipment performance, and strengthening of personnel training. yiruiping® has a complex production process, and yitong has completed the original research and development technology transfer of a complex preparation in just over three years, fully demonstrating the company's high-end technology in the research and development of complex respiratory preparations and professional analysis and testing.

this approval is not only a recognition of eddingpharm's technical strength, but also a practice of the company's commitment to innovation-driven development strategy and its commitment to providing patients with high-quality pharmaceutical products. we have reason to believe that in the near future, eddingpharm® will bring health benefits to more patients with better quality and efficacy, and eddingpharm will continue to contribute more to the prosperity and development of my country's pharmaceutical industry.

(source: financial information)

for more exciting information, please download the "jimu news" client from the application market. please do not reprint without authorization. you are welcome to provide news clues, and you will be paid once adopted.